NextCure, Inc. cotiza a 6.64 USD y tiene una capitalización bursátil de $30M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a no…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-1.85 | $-1.87 | $-0.81 | $-3.22 |
| Estimado | $-1.92 | $-2.03 | $-2.42 | $-3.98 |
| Sorpresa | +3.6% | +7.9% | +66.5% | +19.1% |
| Métrica | NXTC | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -159.8% | -40.4% | -119.4% |
| ROA | -111.3% | -32.0% | -79.3% |
| Current Ratio | 4.14 | 2.84 | +1.30 |
| Debt / Equity | — | 0.28 | — |